Skip to content
Screener

Incyte INCY Accrued Expenses

Accrued Expenses at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$13.47B-22.5%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$1.23M+32.3%
Gilead Sciences logo
Gilead SciencesGILD
$3.7B+3.2%
Geron logo
GeronGERN
$9.11M-19.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$21.67M+40.7%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$74.84M+33.7%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24.28B+60.1%
Enterprise value$20.34B+53.5%
P/E15.1×-2.4×
P/S4.2×+0.9×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemJune 30,2026December 31,2025*
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$250,401$209,938
Accrued compensation148,319228,071
Accrued and other current liabilities870,3061,031,501
Finance lease liabilities4,2594,516
Acquisition-related contingent consideration38,81141,144
Total current liabilities1,312,0961,515,170

Item 1. Financial Statements

FAQ

What is Incyte's accrued expenses?
Incyte (INCY) reported accrued expenses of $148.32M in Q2 2026.
How has Incyte's accrued expenses changed year-over-year?
Incyte's accrued expenses increased by 14.9% year-over-year, from $129.11M to $148.32M.
What is the long-term trend for Incyte's accrued expenses?
Over 5 years (2020 to 2025), Incyte's accrued expenses has grown at a 15.0% compound annual growth rate (CAGR), from $113.34M to $228.07M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about Incyte's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude